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MN with the MicroFlow® due to the cell lysis step and an 
underscoring with the Metafer™ system based on current 
image classifier settings. The findings clearly demonstrate 
that the MicroFlow® and Metafer™ MN scoring platforms 
are powerful tools for automated high-throughput MN 
scoring and dose response analysis.
Keywords Micronucleus · Automation · Dose response · 
Metafer™ · MicroFlow®
Introduction
The in vitro micronucleus assay is a robust platform for 
the assessment of chromosomal damage following the 
treatment of genotoxic agents. In this assay, a quantitative 
measure of the induced chromosomal damage (chromo-
somal breaks and chromosomal loss) is acquired by scor-
ing micronuclei (MN) (Fenech 2000). These events can 
be detected following mitosis, where the lost or broken 
chromosome resides in the cytoplasm, and not the nucleus. 
Traditionally, MN scoring is carried out manually by using 
bright field or fluorescent microscopy. However, the man-
ual scoring procedure has been scrutinised for its subjectiv-
ity and extensive scoring time (Doherty et al. 2011; Seager 
et al. 2014).
To overcome these issues, efforts have been made to auto-
mate the MN scoring platform. These include the use of both 
the semi-automated and the fully automated MN scoring 
approaches that are compatible with multi-endpoint MN anal-
ysis and high-through scoring (Bryce et al. 2007; Varga et al. 
2004). Commercially available platforms such as the Litron 
Laboratories automated flow cytometric platform (Micro-
Flow®) and the semi-automated image analysis platform 
(Metafer™ and Pathfinder™) are among the most widely 
Abstract The use of manual microscopy for the scoring of 
chromosome damage in the in vitro micronucleus assay is 
often associated with user subjectivity. This level of subjec-
tivity can be reduced by using automated platforms, which 
have added value of faster with high-throughput and multi-
endpoint capabilities. However, there is a need to assess 
the reproducibility and sensitivity of these automated 
platforms compared with the gold standard of the manual 
scoring. The automated flow cytometry-based MicroFlow® 
and image analysis-based Metafer™ were used for dose 
response analyses in human lymphoblastoid TK6 cells 
exposed to the model clastogen, methyl methanesulfonate 
(MMS), aneugen, carbendazim, and the weak genotoxic 
carcinogen, ochratoxin A (OTA). Cells were treated for 4 
or 30 h, with a 26- or 0-h recovery. Flow cytometry scoring 
parameters and the Metafer™ image classifier were inves-
tigated, to assess any potential differences in the micro-
nucleus (MN) dose responses. Dose response data were 
assessed using the benchmark dose approach with chemical 
and scoring system set as covariate to assess reproducibil-
ity between endpoints. A clear increase in MN frequency 
was observed using the MicroFlow® approach on TK6 cells 
treated for 30 h with MMS, carbendazim and OTA. The 
MicroFlow®-based MN frequencies were comparable to 
those derived by using the Metafer™ and manual scoring 
platforms. However, there was a potential overscoring of 
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used MN scoring procedures. The Metafer™ MN scoring 
platform is often used in the pharmaceutical industry and in 
academia to assess the genotoxic potential of various DNA 
damaging agents, and it shows a good concordance with con-
ventional MN scoring platform (Chapman et al. 2014).
The MicroFlow® MN scoring platform is proposed as a 
viable alternative to the manual scoring to conduct objec-
tive, multi-parametric MN scoring, with reduced data acqui-
sition time using flow cytometry. Furthermore, the incorpo-
ration of nuclear stains ethidium monoazide (EMA) allows 
discrimination of apoptotic bodies and necrotic cells from 
MN which can be difficult to define manually, and re-prob-
ing with pan nuclear stain SYTOX green following cell lysis 
provides precision MN scoring (Avlasevich et al. 2006). 
Even so, it is likely that chromatin from a certain fraction of 
early-stage apoptotic cells may not always be excluded from 
analysis based on EMA staining. Also, cells with multiple 
MN and multi-nucleated cells with MN would be scored 
differently from lysed (nuclei) preparations compared with 
intact cells. We predict that both of these situations would 
tend to result in somewhat higher flow cytometry-based MN 
frequencies relative to microscopy.
The aim of the present study was to assess the reproduc-
ibility of the MN dose responses generated with the Micro-
Flow® and Metafer™ systems as compared to traditional 
manual scoring. For this purpose, human lymphoblastoid 
TK6 cells were treated with a clastogen (MMS), an aneu-
gen (carbendazim) and a DNA damaging agent (ochra-
toxin A), with the cells scored using the three different 
approaches.
Methods and materials
Chemicals
Methyl methanesulfonate (CAS no. 12925), carbendazim 
(CAS no. 10605-21-7) and ochratoxin A (CAS no. 303-
479) were purchased from Sigma-Aldrich, UK.
Cell lines and treatment
Human lymphoblastoid TK6 cells were obtained from 
American Type Culture Collection (ATCC), Manassas, 
VA, USA. TK6 cells were cultured in RPMI 1640 media 
(Gibco, Paisley, UK), supplemented with 1% pen-strep and 
10% heat inactivated horse serum (Gibco, Paisley, UK). 
Cells were seeded at 2 × 105 cells in 25-cm2 flask (Fisher-
brand), incubated at 37 °C for either 4 or 30 h (1.5–2 cell 
cycles) in the presence of MMS, carbendazim and ochra-
toxin A (OTA). Subsequently, the treatment was removed 
and the cells were harvested following 0- or 26-h recovery 
period. Resulting MN was scored in the absence of cyto-B 
by using the Metafer™ (MetaSystems, Althlussheim, Ger-
many) and the MicroFlow® (Litron laboratories, Rochester, 
USA) platforms. The manual scoring procedure was used 
as a validation tool to verify the results between the Micro-
Flow® and the Metafer™ scoring procedures.
Cytotoxicity and cytostasis
Cell counts were determined using a Coulter counter 
(Beckman Coulter Inc.). Relative population doubling 
(RPD) was used to estimate the highest cytotoxic concen-
tration. MN scoring was restricted to the concentration that 
induced 50% cell death and cytostasis. The RPD calcula-
tion is described in detail elsewhere (Lorge et al. 2008)
Population doubling (PD) was calculated as follows:
The manual scoring procedure
Cells were harvested following 4- or 30-h treatment. 
Briefly, treated cells were transferred to 15-ml centrifuge 
tubes and were centrifuged at 200×g for 10 min. Super-
natant was aspirated, and the pellet was re-suspended in 
10 ml phosphate-buffered saline (Gibco®). Subsequently, 
the cell suspension was cytospun (Cytospin™ centrifuge) 
on a polished glass slides, fixed in 90% ice cold methanol 
for 10 min and were air-dried at room temperature.
Air-dried slides were stained in 4% Giemsa solution 
(VWR International Ltd., Poole, UK) at room temperature. 
Giemsa stained slides were washed under tap water and air-
dried, and a cover slip was mounted on these slides using 
DPX mounting solution. Mononucleated cells with intact 
nuclear and cytoplasmic membrane were considered suit-
able for MN identification. The parameters used for MN 
scoring were size (between 1/3rd and 1/16th the diameter 
of nuclei), morphology (circular or oval) and their associ-
ation with the main nuclei (not linked or overlapping the 
nuclei) (Fenech et al. 2003). The MN scoring was carried 
out by using 20× magnifications on a light microscope 
(Olympus BX 51). The MN frequency was obtained by 
manually assessing 2000 mononucleated cells per replicate. 
A total of 6000 mononucleated cells were scored using the 
manual scoring platform.
Metafer™ analysis
Cells were harvested post-treatment. At the time of har-
vest, treated cells were transferred to 15-ml centrifuge 
%RPD =
Number of population doubling in treated cultures
Number of population doubling in the vehicle control
× 100
PD = Log (Cell count after treatment/
cell count in the control)/log2.
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tubes (Fisherbrand) and centrifuged at 200×g for 10 min. 
Supernatant was aspirated, and the pellet was re-suspended 
in hypotonic solution 5% KCl (KCL, 75 Mm; Sigma-
Aldrich). The cell suspension was centrifuged, supernatant 
was removed, and the pellets were fixed in 5 ml of Fix 1 
[methanol/acetic acid/NaCl (5:1:6)] for 10 min at room 
temperature. Fix2 (methanol/acetic acid 5:1, Fisher Sci-
entific) was used to re-suspend the pellet following cen-
trifugation. Cells were incubated in Fixative 2 for 10 min 
at room temperature and centrifuged at 4 °C, 200×g for 
10 min. These pellets were re-suspended in Fixative 2 and 
stored overnight at 4 °C.
For Metafer™ analysis, 100 μl of cell suspension was 
dropped on to a polished glass slide. Slides were then air-
dried, and 20 µl of 4,6-diamidino-2-phenylindole (Vector 
Laboratories, Peterborough, UK) was use to label nuclei 
and MN. A cover slip was mounted, and slides were incu-
bated for 15 min at room temperature. Subsequently, 
the MN induction was assessed using a semi-automated 
Metafer™ MN scoring platform (Meta System, Alth-
lussheim, Germany). The Metafer MN scoring platform 
consists of a motorised slide loading platform, Carl Zeiss 
Axio Imager fluorescence microscope and a charge-cou-
pled device (CCD) camera. Image acquisition was carried 
out by using Metafer 4 software (version 3.9.8).
Stained slides were loaded on to a motorised slide scan-
ning platform of Metafer system. Slides were scanned; 
images of nuclei and MN were captured with 10× objec-
tive. A 100× objective was used for MN scoring by relo-
cating the cell and MN on the slide form the coordinates 
displayed in the gallery view. Non-overlapping, DAPI 
stained circular/oval nuclei with a size between 1/3rd and 
1/16th of the main nuclei were scored as MN (Fenech et al. 
2003). A total of 18,000 mononucleated cells were assessed 
to enumerate MN frequency.
The MicroFlow® approach
Total 5 × 105 treated cells were transferred to 15-ml cen-
trifuge tube and were centrifuged at 300×g for 5 min. The 
supernatant was aspirated, and the pellets were incubated 
on ice for 20 min. The cells were stained with ethidium 
monoazide (EMA) following 30-min photo-activation. Dur-
ing this incubation period, the cells were placed on ice 2 cm 
below the source of light. This process was used to label 
cell with compromised cytoplasmic membrane. The fold 
change in EMA-positive events was used alongside %RPD 
to estimate increased cytotoxicity and to predict high-
est test concentration. A greater than fourfold increase in 
EMA-positive event was used as an indicator of increased 
apoptosis/necrosis (Bryce et al. 2013). The cytoplasmic 
membrane and the cellular RNA were digested by using 
detergents and RNase solution following photo-activation 
step. Subsequently, the nuclei and MN were labelled with 
SYTOX Green stain. Stained samples were then incubated 
overnight prior to flow cytometric analysis.
Flow cytometric scoring
Prior to the flow cytometric assessments, the suspension 
of sequentially stained nuclei and MN was incubated at 
room temperature for 30 min. Samples were acquired on 
a flow cytometer (BDFACS Aria, BD Biosciences, USA) 
equipped with 488-nm laser, and BD FACS Diva software 
(version 6.1.3) was used for MN scoring. EMA-associated 
fluorescence collected in the FL3 channel was used to mon-
itor increased levels of apoptotic/necrosis. Scoring of nuclei 
and MN was limited to the cells that displayed SYTOX-
associated fluorescence signals in FL1 channel. With the 
MicroFlow® approach, the viable mononucleated cells 
were detected from their SYTOX Green-associated fluores-
cence, DNA content as determined by side scatter and size 
based on the forward scatter characteristics. For an event 
to be classified as MN with the MicroFlow® approach, the 
MN should not be labelled with EMA, exhibit SYTOX 
Green fluorescence between 1/10th and 1/100th for the 
main nuclei and should fall in the side and forward scatter 
regions (Bryce et al. 2007). A total of 24,000 events that 
displayed SYTOX intensities were used to enumerate MN 
frequency.
Statistical analysis
Shapiro–Wilk normality test, Bartlett test or homogeneity 
of variance and Bonferroni test for outlier identification 
were conducted. Data were transformed in order to achieve 
normally distributed data and homogeneity of within-dose 
variance. If the raw or transformed data passed these trend 
tests, then the 1-sided Dunnett’s test was used to identify 
the no-observed and the lowest observed genotoxic effect 
levels (NOGEL, LOGEL) and if the data failed these trend 
tests, then the 1-sided Dunnett’s test was used (Johnson 
et al. 2014).
Covariate benchmark dose (BMD) analysis was carried 
out using PROAST (v60.12) to compare dose responses 
(Slob 2002). This approach relies on constant shape param-
eters for log-steepness and maximum response being used 
between each independent dose response, which provides 
increased precision for each dose response and allows for 
potency ranking to be carried out (Soeteman-Hernández 
et al. 2016; Wills et al. 2016a, b). In this instance, it was 
carried out to observe any trends in equipotency or not 
between the chemicals and MN scoring approach. Over-
lapping BMDs show that equipotency cannot be rejected 
and non-overlapping BMDs show that there is a dif-
ference. Furthermore, when there is no response at the 
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concentrations tested, conserved shape information from 
the other responses is used to fit suitable models to allow 
for BMDL to be derived but with infinite BMDU.
Results
Cytotoxicity and cytostasis
The 50 ± 5% reduction in percentage RPD is a stand-
ardised method to estimate highest test concentration 
for accurate MN enumeration (OECD 2014). The fold 
change in EMA-positive events alongside percentage RPD 
was used to monitor apoptosis/necrosis at the highest test 
concentration.
The concentration of 5 μg/ml MMS was selected as 
the highest test concentration to cause 50 ± 5% cyto-
toxicity, following a 4- or 30-h treatment (Fig. 1a, b). At 
this test concentration, no evidence of increased cyto-
toxicity and cytostasis was seen from the %RPD and 
the fold change in EMA-positive events. In response to 
5 μg/ml MMS, the %RPD dropped to 66% following 
4 h and 56% following 30-h treatment. The fold change 
in EMA-positive events, a 1.7-fold increase following 
4-h treatment and a 2.5-fold increase following a 30-h 
treatment in response to 5 μg/ml MMS, was well below 
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Fig. 1  Cytotoxic and apoptotic/necrotic effects of MMS (a, b), car-
bendazim (c, d) and OTA (e, f) in TK6 cells following 4-h (left-hand 
panel) or 30-h (right-hand panel) treatment. The mean percentage 
RPD (blue solid lines) and EMA-positive fold change (histograms) 
were used as parameters to assess cytotoxicity (n = 3). Overly cyto-
toxic concentration (black box) as indicated by  %RPD or fold change 
in EMA-positive events (≥4 fold increase above the control) or both 
(Bryce et al. 2013) (colour figure online)
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the cut-off (≥4-fold) change for a dose to be considered 
overly cytotoxic.
Carbendazim did not cause any increase in cytotoxicity 
or apoptosis/necrosis in TK6 cells following 4-h treatment 
(Fig. 1c). In contrast, increased apoptosis/necrosis was evi-
dent for the fold change values for EMA-positive events 
following 30-h continuous treatment. Sixfold and 9.5-fold 
increases in EMA-positive events were observed for 1 and 
1.6 μg/ml concentrations. These fold change values for 
EMA staining were greater than fourfold increase above 
the control for these concentrations and hence considered 
overly cytotoxic.
Contradictory results were also seen in TK6 cells fol-
lowing 4-h treatment with OTA. The 18 μg/ml concen-
tration of OTA was identified as overly cytotoxic as 41% 
RPD (59% cytotoxicity) was seen at this dose (Fig. 1e). 
In contrast to %RPD, a 2.5-fold increase in EMA-positive 
fold change was recorded at the same analysed concentra-
tion. Following 30-h continuos treatment, 10 μg/ml OTA 
was identified as overly cytotoxic by both %RPD and fold 
change in EMA-positive events (See Fig. 1f). Therefore, 
MN enumeration was limited to 8 μg/ml concentration of 
OTA following continuous treatment.
Evaluation of MN induction using the automated  
MN scoring platforms
In the case of MMS, discrepancies were seen between 
the MN dose responses when using the Metafer and 
the MicroFlow approaches, following 4-h treatment 
(Fig. 2a). The Metafer scoring platform did not detect 
any significant increase in the MN induction follow-
ing 4-h treatment. In contrast, a significant increase 
in MN frequency was detected at 5 μg/ml MMS when 
scoring was carried out using the MicroFlow approach. 
The mean MN responses were comparable between the 
scoring platforms in TK6 cells treated continuously for 
30 h (Fig. 2b). Both the systems detected a significant 
(p < 0.05) increase in MN induction in response to 2.5 
and 5 μg/ml MMS.
In the cells treated with carbendazim, no increase in 
MN frequency was detected following 4-h treatment by 
either platform. Using the MicroFlow approach, a signifi-
cant increase in MN was observed at 0.8, 1 and 1.6 μg/
ml carbendazim at 30 h. However, increased apoptosis/
necrosis was also seen when measuring fold change in the 
EMA-positive events at 1 and 1.6 μg/ml concentrations. 
The Metafer MN scoring platform detected a significant 
(p < 0.05) increase in MN frequencies at carbendazim con-
centrations of 1 and 1.6 μg/ml.
OTA induced a significant (p < 0.05) increase in the MN 
induction above control at 16 and 18 μg/ml was detected 
by both the MN scoring platforms following 4-h treatment 
(Fig. 2c). In contrast, conflicting results were seen follow-
ing 30-h continuous treatment with OTA (Fig. 2d). In this 
instance, no increase in the MN frequency was detected 
when using the Metafer platform at the analysed test con-
centrations, whereas a clear increase in MN induction 
above the control was seen at 8 μg/ml OTA with the Micro-
Flow approach.
Furthermore, the MN frequencies obtained following 
30-h treatment of MMS, carbendazim and OTA were com-
parable to those obtained in the cytokinesis block micronu-
cleus assay using Metafer platform (please see supplemen-
tary data, Fig. 6)
The manual scoring approach
Significant differences were seen between the MN 
responses derived by using the MicroFlow® and the 
Metafer™ scoring platforms in TK6 cells following a 4-h 
treatment of MMS and 30-h OTA. To resolve this issue, the 
manual scoring procedure was used alongside the Micro-
Flow® and the Metafer™ scoring platforms to assess MN 
induction at 4 h using MMS and carbendazim.
In the case of MMS, MN dose response derived fol-
lowing 4-h MSS treatment by using the manual scor-
ing method was comparable to that of the MicroFlow® 
approach (Fig. 3a). Both the MicroFlow® and manual scor-
ing approaches detected a significant (p < 0.05) increase in 
MN frequency at 5 μg/ml MMS concentration. In contrast, 
no significant increase in MN induction was seen when the 
scoring was carried out using the Metafer™ platform.
Surprisingly, the MN response derived in TK6 cells 
with the manual scoring platform following 4-h treatment 
of carbendazim was different to those obtained using the 
MicroFlow® and the Metafer™ scoring platforms (Fig. 3b). 
In this instance, a significant increase in MN induction was 
observed when manual scoring at 0.8 μg/ml and concen-
trations above it. In contrast, no such increase in the MN 
formation was seen when using the MicroFlow and the 
Metafer scoring platforms.
Covariate BMD analysis
The order of endpoint sensitivity was deduced from the 
covariate BMD analysis, where the horizontal lines repre-
sent the BMDL10-BMDU10 metrics, with the lines in the 
top left being the lowest and most sensitive, and the ones 
on the bottom right being the highest and therefore least 
sensitive. Overlapping lines show equipotency between 
endpoints, and dotted lines represent poor model fits with 
infinite BMDL10 metrics (Fig. 4). The potency evaluations 
show that the MicroFlow approach was the most sensitive 
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Fig. 2  Genotoxic effects of MMS, carbendazim and OTA in TK6 
cells following 4-h (left-hand panel) and 30-h (right-hand panel) 
treatment. The mean MN frequencies derived by the MicroFlow 
(black bars) approach and the Metafer (grey bars) scoring platforms. 
Increased cytotoxicity (black box) as indicated by  %RPD and fold 
change in EMA-positive events (≥4-fold increase above the control). 
Asterisk indicates a significant increase in the MN formation over the 
control using a (p < 0.05). Error bars represent mean ± SD (n = 3). 
The  %RPD values in these graphs are same as those seen in Fig. 1
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Fig. 3  Comparison of the MN responses derived by the MicroFlow 
(black bars), manual scoring (green) and the Metafer (grey bars) in 
TK6 cells treated with MMS and carbendazim for 4 h. Asterisk indi-
cates a significant increase in the MN formation over the control 
using a (p < 0.05). Error bars represent mean ± SD (n = 3) (colour 
figure online)
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when compared to other techniques at 30 h. Using Metafer 
at 30-h chemical exposure was used to accurately char-
acterise MN for all three chemicals, but for OTA it did 
produce wider BMD confidence intervals than the other 
approaches. Metafer at 4-h exposure was not suitable for 
MMS or carbendazim, but was suitable for the assessment 
of OTA.
For MMS, the BMD confidence intervals were indis-
tinguishable between 30-h MicroFlow, 4-h manual, 4-h 
MicroFlow and 30-h Metafer with high precision, whereas 
4-h Metafer provided the least precision in the BMD esti-
mate. For carbendazim at 30-h treatment, the lowest BMD 
metrics were provided by MicroFlow followed by Metafer. 
At 4-h time-point, both Metafer and manual provided 
equivalent metrics, but the MicroFlow did not provide 
a good estimate of the BMD. Following 30-h treatment, 
MicroFlow and Metafer provided equivalent BMD metrics. 
At 4 h, MicroFlow and Metafer provided equivalent BMD 
metrics that were non-distinguishable from 30-h Metafer 
due to the wide confidence intervals, but with higher BMDs 
than for 30-h MicroFlow.
Carbendazim altered the morphology of the micro 
nucleated cells and induced larger MN
The greatest discrepancies among scoring platforms were 
seen for TK6 cells treated with carbendazim. Whilst scor-
ing MN using the manual scoring platform, it was observed 
that the nucleus of these micronucleated cells was cres-
cent-/kidney-bean-shaped. Thus, it was speculated that 
these nuclear anomalies alongside large size MN were 
causing misclassification of micronucleated cells and MN 
with the Metafer scoring platform. The Metafer uses pre-
defined parameters such as the size, aspect ratio, eccentric-
ity and DAPI staining intensity for the detection of nuclei 
and MN (Varga et al. 2004). Therefore, any deviations from 
these parameters for observed nuclei/MN will have a sig-
nificant effect on MN frequency, and such MN cells will 
be excluded resulting into lower proportion of micronucle-
ated cells. Studies with spindle poisons have previously 
shown to induce larger MN in TK6 and NH32 cells (Hashi-
moto et al. 2012). Hence, it was postulated that carbenda-
zim-induced MN were larger and thus not appropriately 
Fig. 4  MN BMD Covariate analysis, potency ranking, from most potent/sensitive top left to least potent/sensitive bottom right. X-axis, Log10.
dose (μg/ml). Carb, carbendazim; 30, 30-h treatment; 4, 4-h treatments, flow, MicroFlow; met, Metafer; man, manuals scoring
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identified by Metafer classifier that had been standardised 
on micronucleated cells induced by clastogens. Hence, fur-
ther MN scoring in TK6 cells treated with Carbendazim 
was carried out manually by using florescent microscopy in 
cells stained with DAPI and chromosomes counter stained 
with human pan centromeric probes. With this dual staining 
approach, two parameters such as the morphology of the 
micronucleated cells and the number of centromeric signals 
with the MN were evaluated to address the issue of under-
scoring with the Metafer system. A total of 100 micronu-
cleated cells were assed for the occurrence of larger MN 
(MN with 2 or more centromeric signals) and morphologi-
cally altered MN cells.
Carbendazim caused a concentration-dependent increase 
in the number of micronucleated cells with morphologi-
cally abnormal nuclei (Fig. 5a) and large size MN (Fig. 5b) 
in TK6 cells treated for 4 h. These results clearly indicate 
that the classifier standardised for detecting MN induced by 
clastogens might not be suitable to detect MN induced by 
aneugens.
Discussion
The reproducibility, sensitivity and transferability of the 
MicroFlow® and Metafer™ approaches were compared 
with manual scoring through analyses of the dose response 
data. Using this approach, the MicroFlow® data were com-
parable to the Metafer™ data for MMS, carbendazim and 
OTA, although there was a clear difference in the MN 
response magnitude. This difference could be due to under-
scoring by Metafer™ current classifier settings, where cells 
with novel nuclear morphology are not identified, or where 
there is misclassification of large MN as nuclei. How-
ever, this could be overcome with a visual detection step 
(Decordier et al. 2009), or an updated classifier. A potential 
for overestimation of the MN frequencies with the Micro-
Flow® approach could be due to the cell lysis step, where 
MN is not always associated with a single mononuclear 
cell. In both cases, the fold change in EMA-positive events 
along side %RPD was considered suitable to estimate cyto-
toxic concentration and to study apoptosis/necrosis.
The flow-based MN scoring procedure provides ben-
efits over manual scoring and, to an extent, semi-automated 
Metafer in terms of high-throughput MN scoring and mul-
tiplexing. With the MicroFlow approach, 10,000 events 
(cells) can be scored within a minute, whereas it takes up to 
3 min to visually certify images of MN derived from 3000 
thousands cells with Metafer and 15 min to visually inspect 
1000 cells with the manual scoring platform. In addition to 
automated MN scoring, the MicroFlow approach permits 
assessment of additional cellular parameters such as cell 
cycle changes and apoptosis/necrosis which are otherwise 
difficult to assess using the conventional platforms. The 
BMD covariate analysis showed that for MMS and OTA, 
the Metafer and MicroFlow approaches produced equiva-
lent BMD metrics, but for the aneugen carbendazim, the 
MicroFlow provided the most sensitive BMD estimates 
which were achieved at 30-h treatment. However, at 4 h, 
neither the Metafer or MicroFlow approaches were suitable 
for deriving BMD metrics.
One major disadvantage of using the MicroFlow MN 
approach is the inability to differentiate bi-, tri- and multi-
nucleated cells with MN and cells with multiple MN. This 
can lead to elevated MN frequencies compared with analy-
ses conducted with intact cells. This effect was seen clearly 
in response to MMS and Carbendazim (Fig. 2). Doherty 
et al. (2014) also observed an increase in the frequency of 
micronucleated bi-nucleated cells with MMS in non-cyto-B 
treated cells (Doherty et al. 2014). Additionally, the origin 
of the MN via clastogenic or aneugenic mechanisms can-
not be elucidated following cell lysis procedure with the 
MicroFlow approach, although some cell lines (e.g., CHO-
K1) are reported to provide aneugenicity signatures that 
include hypodiploidy and increased median MN fluores-
cence intensity (Bryce et al. 2010).
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Fig. 5  FISH to assess the induction of larger MN (a) and assessment of morphologically altered MN cells (b) in TK6 cells treated with carben-
dazim
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There are some issues in using the MicroFlow® 
approach, such as re-validation of the misleading positive 
and negative result following cell lysis and flow cytomet-
ric analysis and stained samples cannot be store for a long 
period when compared with Metafer and manual scoring 
where slide can be store for months (Fenech et al. 2013). 
However, there are also some disadvantages when using the 
Metafer system, with the major one being that some MN 
events are not picked, which leads to the underscoring as 
shown in the dose responses for all the three chemicals 
(Fig. 2). Since the samples were prepared from the same 
treated culture it was postulated that the Metafer™ clas-
sifier settings were incompatible for scoring MN induced 
by the aneugen Carbendazim. With the Metafer™ plat-
form, the classifier is configured to assess parameters such 
as shape, circularity, aspect ratio and size to detect nuclei 
and MN (Reference). Therefore, it is possible that subtle 
changes in the morphology of nuclei/MN and induction of 
larger MN could cause underscoring with this system. The 
FISH and morphological studies provided some evidence 
on the induction of larger MN and morphologically altered 
nuclei in TK6 cells exposed to Carbendazim (Fig. 5a, b), 
which is in line with previous studies (Hashimoto et al. 
2010). However, a larger sample size and increase doses 
are required to confirm these findings for carbendazim, and 
this hypothesis also needs to be tested on other aneugens. 
The advantages and disadvantages of the each of these dif-
ferent scoring methodologies for scoring MN are summa-
rised in Table 1. In order for these approaches to be more 
widely used for MN scoring and dose response analysis, 
future ring trials should focus on addressing these consid-
erations as well as assessing interlaboratory reproducibility.
Both the MicroFlow and Metafer scoring approaches 
are suitable for automated MN scoring. However, in cases 
of equivocal with chemicals with unknown activity, it may 
be advisable to additionally process the same treated sam-
ples for manual scoring. These manually scored slides can 
be used to reduce the occurrence of misleading results, 
assess cytotoxicity or conduct mechanistic studies. Whilst 
conducting MN scoring on the semi-automated Metafer 
system, the classifier setting should be adopted to account 
for chemical or cell line-specific morphological changes 
and to reduce the occurrence of misleading results (positive 
and negative). These semi-automated and fully automated 
platforms can therefore be used for dose response analysis 
as substantially higher number of cells can be scored with 
these methods which allows for much statistical power.
A test system that combines the high high-throughput, 
high-content and multiplexing potential of flow cytometry, 
with the re-validation and data storage benefits for image 
analysis, would be a major step forward in achieving a truly 
twenty-first century approach.
Table 1  Summary of the advantages and disadvantages of manual, Metafer™ and the MicroFlow® approaches
MN scoring approaches Scoring platforms Advantages Disadvantages
Image analysis Manual microscopy (light  
microscopy)
Suitable for dose response and mode 
of action analysis
Simple, economical and adaptable
Suitable for MN scoring in the pres-
ence or the absence of cyto-B
Stained slides can be stored for a 
long time and can be re-analysed
Suitable for assessing bi-, tri- and 
poly-nucleated cells
Interoperational variations can result in 
subjective MN scoring
Slow, tedious and time-consuming
Lack multiplexing abilities
Total number of cells scored manually 
is limited which reduces the overall 
statistical power
Metafer™ (fluorescent  
microscopy)
Semi-automated platform
High content for higher statistical 
precision
Suitable for dose response and 
mode of action analysis for most 
substances
Images of nuclei and MN can be 
stored for re-validation
Classifier settings have to be optimised 
for different cell lines and chemicals 
that induce MN via varied mecha-
nisms
Lack of cytoplasmic staining, detection 
of small MN and manual validation 
of the images
Flow cytometry MicroFlow® Fully automated platform to score 
MN objectively
Suitable for dose response
High content and high throughput
Permits cell cycle analysis
10,000 events scored in 1–2 min
Cell lysis is required prior to MN 
scoring
Misleading MN cannot be re-validated 
from same sample
Overestimation and underestimation 
of MN are both possible and require 
expert analysis
Lack of MOA analysis with TK6 cells
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